Last update Jan. 10, 2015

Cabergoline

High Risk

Poorly safe. Evaluate carefully. Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives). Read the Comment.

Ergot derivative alkaloid which is used to suppress lactation by inhibiting Prolactin release. Also used with levodopa for treatment of Prolactinoma and Parkinson disease.

No untoward effects have been reported in breastfed infants of mothers who were treated (or erroneously had received medication) and decided to resume breastfeeding.

Non-pharmacological methods used to suppress lactation are as effective as pharmacological ones.

Alternatives

We do not have alternatives for Cabergoline.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Cabergoline is also known as


Group

Cabergoline belongs to this group or family:

Tradenames

Main tradenames from several countries containing Cabergoline in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 100 %
Molecular weight 452 daltons
Protein Binding 41 %
Tmax 3 hours
T½ 80 hours

References

  1. Trimeloni L, Spencer J. Diagnosis and Management of Breast Milk Oversupply. J Am Board Fam Med. 2016 Abstract Full text (link to original source) Full text (in our servers)
  2. PDR.net Cabergolina Drug Summary 2014 Full text (in our servers)
  3. Eglash A. Treatment of maternal hypergalactia. Breastfeed Med. 2014 Abstract Full text (link to original source) Full text (in our servers)
  4. Auriemma RS, Perone Y, Di Sarno A, Grasso LF, Guerra E, Gasperi M, Pivonello R, Colao A. Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation. J Clin Endocrinol Metab. 2013 Abstract Full text (link to original source) Full text (in our servers)
  5. [No authors listed] Do not use drugs to prevent onset of lactation. Relieve the discomfort and wait. Prescrire Int. 2013 Abstract
  6. Shahzad H, Sheikh A, Sheikh L. Cabergoline therapy for macroprolactinoma during pregnancy: a case report. BMC Res Notes. 2012 Abstract Full text (link to original source) Full text (in our servers)
  7. AEMPS Cabergolina Ficha Técnica 2011 Full text (link to original source) Full text (in our servers)
  8. [No authors listed] Single dose cabergoline versus bromocriptine in inhibition of puerperal lactation: randomised, double blind, multicentre study. European Multicentre Study Group for Cabergoline in Lactation Inhibition. BMJ. 1991 Abstract Full text (link to original source) Full text (in our servers)
  9. Caballero-Gordo A, Lopez-Nazareno N, Calderay M, Caballero JL, Mancheño E, Sghedoni D. Oral cabergoline. Single-dose inhibition of puerperal lactation. J Reprod Med. 1991 Abstract
  10. Melis GB, Mais V, Paoletti AM, Beneventi F, Gambacciani M, Fioretti P. Prevention of puerperal lactation by a single oral administration of the new prolactin-inhibiting drug, cabergoline. Obstet Gynecol. 1988 Abstract

Total visits

91,979

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM